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Gliomas represent a serious medical problem that continue to defy
successful treatment. While surgery and radiotherapy generally
add several months to a year of life to patients, the tumour
inevitably recurs, most often leading to death within 6 months
(Radhakrishnan et al, 1994). Chemotherapy has also proven
generally unsuccessful in the treatment of gliomas. Despite major
advances in the development of new chemotherapeutic agents, the
treatment of gliomas has not been significantly impacted. At least
one reason for the lack of significant effects of chemotherapy is
the existence of the blood–brain tumour barrier (BBTB). Like the
blood–brain barrier (BBB), the BBTB is comprised of vascular
endothelial cells whose cytoarchitecture and closely packed
arrangement preclude water soluble drugs from easily diffusing
from the vessel lumen into the brain (tumour) space. While the
BBTB is generally more leaky than the normal BBB, the barrier
nonetheless persists in tumour vessels and represents a formidable
obstacle to the delivery of potentially valuable drugs to brain
tumours (Black, 1995).
Research extending over the past 2 decades has explored the
concept that the permeability of the BBB and BBTB might be
temporarily increased to deliver greater amounts of drugs into the
brain and brain tumours respectively. This work was pioneered by
investigators who infused hyperosmotic agents, such as mannitol
and arabinose, directly into the carotid artery to temporarily
disrupt the barriers (Neuwelt and Rapoport, 1984; Neuwelt et al,
1984a, 1985). These attempts were refined as investigators used
endogenous peptides to increase the permeability of the vascular
barriers by activating specific receptors expressed on the endo-
thelial cells comprising the BBB and BBTB. The most noteworthy
effort, to date, has occurred with the paracrine peptide, bradykinin
(Wahl et al, 1987; Inamura & Black, 1994; Nomura et al, 1994).
Most recently, CereportTM (RMP-7) has been developed as the first
receptor agonist to increase permeability of the BBB (Sanovich et
al, 1995). Cereport is a bradykinin analogue which has a longer
half-life and greater selectivity for the constitutively expressed B2
receptor (compared to bradykinin), thus providing two essential
characteristics required of a drug intended to activate cerebral
vascular receptors following parenteral administration (Doctrow et
al, 1994; Straub et al, 1994; Bartus et al, 1996b).
Over the past several years, Cereport has been developed speci-
fically as a means to increase delivery of chemotherapeutic agents
to brain tumours. Testing in animal models of glioma (Inamura et
al, 1994; Elliott et al, 1996a, 1996b, 1996c; Matsukado et al, 1996,
1998), as well as imaging studies in glioma patients (Warkne et al,
1995; Ford et al, 1996; Black et al, 1997) have demonstrated that
Cereport not only increases permeability of the vasculature
supplying brain tumours, but does so selectively. That is, the
increased permeability is approximately 10–20 times greater in
brain areas associated with tumours, as compared to normal, non-
tumour brain (Bartus et al, 1996b). Recent phase II clinical trails
in recurrent glioma offer preliminary evidence of patient benefit
from Cereport when combined with carboplatin (Gregor et al,
1997; Prados et al, 1997; Chow et al, 1998) and a multinational
phase III trial has been initiated for primary glioma.
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The concept of using a receptor agonist such as Cereport to
increase permeability of the BBTB, and thereby increase drug
concentrations in brain tumours, represents a radical departure
from the way in which brain tumours have been treated tradition-
ally. Accordingly, a number of unique issues arise, because simply
achieving the conventional ‘maximum tolerated area under the
curve (AUC)’ of the chemotherapeutic drug may no longer yield
optimal effects. Instead, attention must not only be given to the
dose of both drugs administered but also, importantly, to the
precise timing of their administration. These points become even
more clear when one considers the complex pharmacodynamics
involved with receptor-mediated modulation of the BBTB. For
example, the increase in permeability induced by Cereport is tran-
sient, persisting for only about as long as the Cereport infusion
lasts. In less than 2 min following the termination of Cereport
infusions, restoration of the barrier occurs (Bartus et al, 1996a).
Tachyphylaxis, or the gradual loss of pharmacological activity, has
also been noted with intracarotid Cereport infusion, reflected by
spontaneous restoration of the barrier within 30–60 min of contin-
uous Cereport administration (Bartus et al, 1996a, 1996b). Thus,
the precise timing of the Cereport infusion and that of the
chemotherapeutic agent is crucial to whether any increased uptake
into brain tumours will occur. However, the complex and transient
nature of Cereport’s effect on BBB permeability makes it difficult
to predict what the optimal dosing paradigm might be. In prin-
ciple, the time that the barrier is opened most widely should
coincide with the peak plasma levels of the chemotherapeutic.
Beyond that, knowing how quickly the barrier begins to open with
Cereport, whether this response is graded or all-or-none, and
precisely when tachyphylaxis first begins to occur will all influ-
ence the extent to which different combinations of dosing parame-
ters enhance uptake of chemotherapeutic agents into the tumour.
To date, no systematic attempt has been made to address these
issues with Cereport or any other receptor-mediated approach
to modulating the BBTB. Thus, a series of experiments were
conducted comparing different dosing combinations of Cereport
and carboplatin in an attempt to further elucidate the pharmaco-
dynamics involved with B2 receptor-mediated changes in BBTB
permeability, and identify principles and dosing paradigms likely
to be of benefit in the clinic.
MATERIALS AND METHODS
Rodent glioma model
Subjects
Male Fischer rats (n = 286, 170–220 g; Taconic Farms, German-
town, NY, USA) were used in these studies. The rats were housed
in pairs in polypropylene cages with free access to food and water.
All procedures were reviewed and approved by Alkermes’ Animal
Care and Use Committee and were conducted in a manner which
met or exceeded NIH standards.
Tumour cell implantation
Rat glioma (RG2) cells were maintained and implanted as previ-
ously described (Bartus, et al, 1996a, 1996b; Elliott et al, 1996a,
1996b). Briefly, rats were anaesthetized with a solution containing
ketamine (24 mg ml–1), xylazine (1.3 mg ml–1) and acepromazine
(0.33 mg ml–1) and placed in a stereotaxic instrument. RG2 cells
(5 ´ 104 cells per 5 ml) were injected unilaterally into the striatum
using a stereotaxic-mounted 10-ml Hamilton syringe with a
22-gauge needle at the following coordinates: A–P (+2.0 mm),
L (+3.0 mm) and V (–6.5 mm) (Pellegrino et al, 1986).
Dosing paradigm
Blood vessel cannulation
One week after tumour implantation, and under urethane anaes-
thesia (1.8 g kg–1; intraperitoneally (i.p.), cannulae were placed in
the jugular vein for drug administration and into both femoral
arteries for the measurement of physiological parameters and the
collection of blood used to calculate the uptake constant, Ki (e.g.
see Elliott et al, 1996a, 1996b).
Drug administration and physiological monitoring
Cereport (Alkermes, Inc., Cambridge, MA, USA) was dissolved
in sterile 0.9% saline and infused intravenously (i.v.) using an
infusion pump at a rate of 0.05 ml per min. Based on prior
dose–response data collected with Cereport (Bartus et al, 1996b;
Elliott et al, 1996a), the pharmacologically active doses of 4.5 and
9.0 mg kg– were used. [14C]carboplatin (SA = 144 mCi mg–1;
Amersham, Arlington Heights, IL, USA) was given as either a
bolus (100 mCi ml–1 kg–1) over 3 s or as a 15 min infusion into the
jugular vein as described below (Figure 1). Throughout the exper-
iment, body temperature was maintained normothermic (37.0 ±
1.0°C) and arterial blood gases, pH and blood pressure were moni-
tored as previously described (Bartus et al, 1996a, 1996b; Elliott et
al, 1996a, 1996b). Animals with physiological values outside the
normal ranges (10–15% of all animals) were not used.
Quantitative measurements
Carboplatin pharmacokinetic plasma profile
To determine the pharmacokinetic plasma profile of carboplatin,
rats (approximately 225 g) were injected through the jugular vein
cannula with either a bolus injection or 15 min infusion of
[14C]carboplatin (100 mCi kg–1). Blood samples (300 ml) were
taken via a femoral artery cannula during and following the radio-
label injection. Five animals received bolus injections of
[14C]carboplatin and had blood samples withdrawn at 1, 3, 5, 10,
15 and 20 min after the carboplatin injection. Sixteen animals
received carboplatin infusions, and had blood withdrawn at 1, 3, 6,
9, 12, 24, or 30 min. To control for the possibility that the reduced
blood volume would confound the AUC determinations, the total
number of samples from individual animals ranged from 4 to 10
and was randomly distributed across the range of time sampling
points. Accordingly, the total loss of blood ranged from 7.5% to
18% for individual animals. Radioactivity levels in the blood
samples were determined using liquid scintillation counts.
Following the determination of the plasma levels of radiolabelled
carboplatin, the carboplatin AUC was determined for all animals
using the linear trapezoidal method.
Enhanced delivery of radiolabelled carboplatin
For determination of carboplatin uptake into tumour tissue, arterial
blood was withdrawn into PE90 tubing at a constant rate
(0.04 ml min–1) following administration of the radiolabel and
prepared for scintillation counting, as previously described (Bartus
et al, 1996a, 1996b; Elliott et al, 1996a, 1996b). At the end of the
drug administration protocol, rats were decapitated, their brains
rapidly removed, and the tumour was carefully dissected free.
Tissue samples were weighed and incubated overnight at 40°C in966 DF Emerich et al
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1 ml of Soluene. The following day, 10 ml of Hionic Fluor was
added and radioactivity (nCi g–1) was computed using scintillation
counts. To account for differences in carboplatin concentration
gradients under the various dosing paradigms used, the unidirec-
tional transfer constant, Ki, was calculated as described earlier
(Ohno et al, 1978; Ziylan et al, 1988), to provide an additional
measure of the amount of [14C]radiolabel taken up into tumour
tissue.
Statistics
Both the carboplatin pharmacokinetic plasma profiles and the
effects of Cereport on delivery of carboplatin were compared in
rats using a one-way analysis of variance (ANOVA) and post-hoc
Dunnett’s tests for multiple comparisons between control and
treatment groups (JMP, SAS Institute Inc., Cary, NC, USA).
RESULTS
Bolus vs intravenous infusion of carboplatin
The initial experiment in this series compared the ability of i.v.
infusions of Cereport to increase the levels of carboplatin in
glioma, when carboplatin was given either as a bolus, or as a
15 min co-infusion (Figure 1). As shown in Figure 2, i.v. Cereport
(9.0 mgk g –1) increased carboplatin into the tumour by 75.5%
(P < 0.05) when carboplatin was given as a bolus 5 min into the
Cereport infusion. However, when Cereport and carboplatin were
administered as 15 min co-infusions, no enhanced levels of carbo-
platin were seen at either of the two doses tested (P > 0.1).
Qualitatively, the carboplatin plasma profile achieved with the
bolus was notably different from that achieved with a 15 min infu-
sion. With the bolus injection, the peak plasma concentration or
Cmax was higher, while the timing of its occurrence was earlier, as
expected (Figure 3). However, when the AUC was calculated
within the time frame that Cereport was infused, the two dosing
paradigms produced AUCs that differed by less than 20% (bolus =
5745 ± 338 nCi; infusion = 4464 ± 61 nCi; P < 0.01).
Test for tachyphylaxis
The ability of Cereport to increase tumour levels of carboplatin
was dependent on the timing of the carboplatin bolus relative
to the initiation of the Cereport infusion. A significant, 174%
increase in carboplatin levels was seen when carboplatin was
given 5 min into the Cereport infusion (P < 0.01). When the carbo-
platin bolus was given 10 min into the Cereport infusion, a signifi-
cant (P < 0.05), but lesser effect of 112.4% was observed. Finally,
when carboplatin was given 15 min from the initiation of the
Cereport infusion, no increase in carboplatin levels was observed
(P > 0.1), indicating that the barrier had restored (Figure 4). Thus,
these data indicate that with constant i.v. infusions of Cereport, the
effects on the BBTB exhibit tachyphylaxis (i.e. a gradual diminu-
tion in the pharmacological response over time).
Refinement of dosing protocol
Contrary to the earlier co-infusion paradigm, Cereport enhanced
tumour levels of carboplatin (by 142%; P < 0.01) when the
infusion of Cereport was delayed and overlapped the carboplatin
infusion by 5 min (Figure 5A). In contrast, when Cereport was
administered only after the carboplatin infusion ended, the change
in carboplatin tumour levels were negligible (i.e. less than 25%:
Figure 5A). Similarly, when the data was converted to the uni-
directional transfer constant (Ki) to account for possible effects of
differences in plasma carboplatin concentrations, a significant
increase in carboplatin delivery to tumour was observed in the
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Figure 1 (A) Schematic representation of the carboplatin infusion paradigm
used to test the hypothesis that tachyphylaxis occurs during a 15 min i.v.
infusion of Cereport. Animals received a 15 min i.v. infusion of Cereport
and a bolus injection of [14C]carboplatin at either 5 (early), 10 (middle), or
15 (late) min from the start of the Cereport infusion. All animals were
sacrificed 10 min following the bolus injection of [14C]carboplatin. (B) Infusion
paradigms used to evaluate the effects of Cereport on [14C]carboplatin levels
when the Cereport and carboplatin infusions were overlapping (top) and
sequential (bottom). All animals received a 15 min infusion of carboplatin.
One group of animals (overlapping infusions) received a 10 min i.v. infusion
of Cereport beginning 10 min into the carboplatin infusion. A second group of
animals (sequential infusions) received Cereport beginning immediately at
the end of the [14C]carboplatin infusion. All animals were sacrificed 15 min
following the initiation of the Cereport infusionCereport-enhanced delivery of carboplatin into brain tumours 967
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overlapping (65% increase; P < 0.05) but not the sequential dosing
paradigm (Figure 5B).
An analysis of the plasma concentrations of carboplatin under
the overlapping and sequential paradigms revealed a modest
(< 20%) but significant increase in carboplatin concentrations in
the Cereport group (Table 1; P < 0.01) relative to saline-treated
animals. No significant interaction was observed between dosing
condition (overlapping vs sequential) and Cereport (P > 0.1).
DISCUSSION
Cereport represents the first compound in a new approach to treat
malignant gliomas: receptor-mediated modulation of the BBTB to
increase delivery of hydrophilic drugs to brain tumours. Previous
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Figure 2 Concentration of [14C]carboplatin in tumour following a 15 min i.v.
infusion of either saline or Cereport. The left panel represents the effects of
Cereport (9.0 mg kg–1) on carboplatin levels in tumour following a bolus
injection of carboplatin given 5 min into the Cereport infusion (n for vehicle =
49, for Cereport = 50). The right panel depicts carboplatin levels following
simultaneous co-infusions of vehicle (n = 20) or Cereport and carboplatin
(Hatched bar = 4.5 mg kg–1, n = 11; solid bar = 9.0 mg kg–1, n = 14). Note that,
in contrast to a bolus injection, co-infusions do not produce any effect on
carboplatin levels in tumours. Data presented are mean ± s.e.m. nCi g–1
tissue. *P < 0.05 vs saline
Figure 3 Carboplatin plasma profile following infusions and bolus injections
of [14C]carboplatin. (A) The carboplatin plasma AUC (shaded area) following
a 15 min i.v. infusion of labelled carboplatin together with a 15 min
co-infusion of Cereport. (B) The AUC when the labelled carboplatin was
administered as a bolus injection 5 min into the Cereport infusion
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Figure 4 Tachyphylaxis to a 15 min i.v. infusion of Cereport (9.0 mg kg–1)
using the paradigm outlined in Figure 1A. [14C]carboplatin was administered
as a bolus injection at 5 min into the saline infusion (n = 12) and 5 (n = 13) or
15 (n = 13) min into the Cereport infusion. Note that significant increases in
carboplatin levels occur after 5 and 10, but not 15, min of continuous
Cereport. Data presented are mean ± s.e.m. nCi g–1 tissue. *P < 0.05 vs
saline
Table 1 Carboplatin plasma concentrations (nCi ml–1 ± s.e.m.) under
overlapping and sequential dosing conditions
Condition Overlapping paradigm Sequential paradigm
Saline 210.0 ± 8.21 214.0 ± 13.6
Cereport 269.0 ± 14.9* 233.9 ± 9.90*
Carboplatin plasma concentrations were calculated using blood obtained
beginning at the start of the 10 min Cereport infusion and continuing for an
additional 5 min. Cereport induced a modest increase in concentration in
both the overlapping and sequential dosing conditions (*P < 0.01) vs saline-
treated animals.968 DF Emerich et al
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work with animal models demonstrated that Cereport significantly
increases uptake of carboplatin into brain tumours in a selective
manner, in that the effect in non-tumour brain is 0.05 to 0.10 that
of brain tumour-associated tissue (Bartus et al, 1996b). Evidence
of Cereport’s selectivity to tumour vasculature has been confirmed
in the clinic using imaging techniques in glioma patients (Ford et
al, 1996; Black et al, 1997). These preliminary clinical studies in
human recurrent gliomas have also suggested that Cereport
combined with carboplatin provides increased patient benefit
when compared to carboplatin alone (Prados et al, 1997) or
standard care (Gregor et al, 1997).
The experiments presented in this manuscript: (1) provide the
first systematic evaluation of different i.v. dosing paradigms of
Cereport; (2) contribute to the empirical foundation being built for
receptor-mediated modulation of the BBTB; and (3) provide new
information to aid in the design of future clinical trials and inter-
pretation of the data collected. In summary, the results of these
experiments demonstrate that i.v. infusions of Cereport signifi-
cantly increase the concentration of carboplatin delivered to
tumours, but these effects can vary dramatically, depending upon
the specific temporal dosing parameters. Furthermore, these varia-
tions are due, in part, to the transient nature of the changes in
BBTB permeability induced by Cereport.
Tachphlyaxis as an important dosing issue
The initial experiment demonstrated that Cereport allowed signifi-
cantly more carboplatin into the tumour when the latter was given
as a bolus, but not when the two drugs were simultaneously
infused over 15 min. This difference occurred despite relatively
subtle differences in carboplatin plasma AUCs (i.e. < 20%) during
the time that Cereport was infused (and therefore during the time
permeability of the BBTB was increased) (Bartus et al, 1996a,
1996b). We hypothesized that the complete lack of an apparent
effect in the co-infusion paradigm could be due to diminished
permeability from i.v. Cereport during the latter portion of the
15 min, continuous infusion (i.e. that tachyphylaxis to Cereport’s
effects occur within the 15 min i.v. infusion). The second experi-
ment in the series demonstrated that the permeability effects of
Cereport do diminish during the 15 min infusion, in that the effects
were greatest during the initial 5 min epoch, being approximately
twofold higher than the values for the last 5 min epoch. These data
support a classic, tachyphylaxis interpretation.
While this new evidence for tachyphylaxis is generally reminis-
cent of that reported previously with intracarotid Cereport (Bartus
et al, 1996a, 1996b), the phenomenon reported here occurred
several times more rapidly (e.g. in 15 min vs 60 min). The reason(s)
for the difference in the rate of tachyphylaxis between studies are
uncertain, but one salient difference is that the earlier studies used
intracarotid infusions of Cereport, while the present study used i.v.
infusions. With intracarotid Cereport, tachyphylaxis can be avoided
or overcome if subsequent doses of Cereport are greater (Bartus et
al, 1998). If the corollary is true, the lower Cereport concentrations
at the cerebral vascular receptors that occur with i.v. dosing may
permit tachyphylaxis to occur even more rapidly than is observed
with intracarotid infusions. Consistent with this hypothesis is the
observation that tachyphylaxis can be induced with low, near-
threshold concentrations of Cereport (Bartus et al, 1996a).
Alternatively, the increased rate of tachyphylaxis observed here
may reflect subtle differences in this phenomenon when F344 rats,
syngeneic to the RG2 tumour cells, are used (as was done in the
present case), as opposed to when the outbred Wistar strain is used
(as was true of the earlier, intracarotid studies). Further work will
be required to confirm the difference observed and to test the
hypotheses it suggests. Nonetheless, the tight, autoregulation of the
permeability effect that is represented by tachyphylaxis further
emphasizes the relative safety of a receptor-mediated approach to
modulating the BBTB – a point also supported by direct animal
(Riley et al, 1998) and human safety studies (Grous et al, 1996).
70
60
50
40
30
20
10
0
C
o
n
c
e
n
t
r
a
t
i
o
n
 
o
f
 
[
1
4
C
]
c
a
r
b
o
p
l
a
t
i
n
 
i
n
 
t
u
m
o
u
r
(
n
C
i
 
g
–
1
)
U
p
t
a
k
e
 
o
f
 
[
1
4
C
]
c
a
r
b
o
p
l
a
t
i
n
 
i
n
 
t
u
m
o
u
r
( K
i
 
(
m
l
 
g
–
1
 
m
i
n
–
1
)
Vehicle Cereport
Overlapping
Vehicle Cereport
Sequential
Vehicle Cereport
Overlapping
Vehicle Cereport
Sequential
35
30
25
20
15
10
5
0
B
A
Figure 5 (A) Effects of manipulating the timing and duration of Cereport
and [14C]carboplatin infusions as outlined in Figure 1B. All animals received
15 min i.v. infusions of labelled carboplatin together with a 10 min infusion of
Cereport. A 10 min infusion of Cereport (9.0 mg kg–1) increased carboplatin
levels into tumours when its infusion overlapped the carboplatin infusion (left
panels; n = 18 for vehicle and 19 for Cereport) but not when the Cereport
infusion followed the carboplatin infusion (right panels; n = 16 for vehicle and
17 for Cereport). Data presented are mean ± s.e.m. nCi g–1 tissue. *P < 0.05
vs. saline. (B) Representation of the same data as Figure 5A, but converted
to unidirectional transfer constant (Ki) to account for possible effects of
differences in plasma carboplatin concentrations. Note that the overlapping
paradigm still produced a significant effect of Cereport, while the sequential
paradigm did not. Data presented are mean ± s.e.m. Ki (ml g–1 min–1)
carboplatinCereport-enhanced delivery of carboplatin into brain tumours 969
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On the other hand, future work directed toward understanding
and possibly delaying tachyphylaxis might reduce dosing
restrictions that the phenomenon currently imposes. While the
mechanism for Cereport tachyphylaxis is unknown, studies with
bradykinin in other systems indicate that internalization and proteo-
lytic degradation of the receptor occurs following its activation
(Munoz and Lee-Lundberg, 1992). This response, and/or depletion
of several second messengers associated with bradykinin signal
transduction (including stimulation of G proteins, phosphoinositide
turnover, prostaglandin response, and activation of both guanylate
and adenylate cyclase) (Burch et al, 1993), are worthy of future
investigations aimed at defining the mechanism of tachyphylaxis.
These data therefore emphasize a principle which may apply
to all therapeutic approaches intended to increase delivery of
chemotherapeutic drugs across the BBTB. That is, simply
achieving the maximum tolerated AUC of the chemotherapeutic
agent may produce disappointing results, for the precise timing of
the Cmax and the surrounding slopes of the plasma curve must
also be considered, relative to when permeability of the barrier is
maximally increased. Accordingly, important prerequisites to
employing this and similar receptor-based approaches to treating
gliomas involve: (a) an accurate characterization of the plasma
pharmacokinetic profile of the chemotherapeutic; (b) knowledge
about the precise timing of the pharmacodynamics of the intended
increase in permeability; and (c) a clinical dosing protocol that
effectively incorporates this information by closely linking the
timing of the two.
Issues for refining Cereport dosing paradigms
These data demonstrate that increased delivery of carboplatin to
tumour can be achieved following i.v. infusions of both Cereport
and carboplatin, specifically when the infusion of Cereport is
delayed until the plasma levels of carboplatin are substantially
elevated. The data also offer further support for the hypothesis that
simultaneous i.v. co-infusions of Cereport and carboplatin failed to
produce significant increases in carboplatin levels because tachy-
phylaxis occurred during the 15 min Cereport infusion (i.e. prior to
sufficient carboplatin plasma levels being achieved via co-infu-
sion). However, what is not easy to explain is the lack of an effect
when Cereport was administered at the end of the 15 min carbo-
platin infusion. The carboplatin pharmacokinetic plasma profile
indicates that the AUCs during the Cereport infusion in the two
dosing conditions are reasonably comparable (see Figure 3; t =
10–25 min vs t = 15–30 min). Thus, one would have expected the
two dosing conditions to produce reasonably comparable carbo-
platin values in the tumour, but they did not.
Conceivably, Cereport might influence carboplatin protein
binding in blood. However, tests of carboplatin protein binding in
human blood (AV Boddy and HD Thomas, personal communica-
tion) and rat blood (unpublished observations) indicated that very
little carboplatin binds to plasma proteins within the time frame
of our experiments and that Cereport did not affect the extent of
carboplatin protein binding.
Another possibility is that Cereport changed the plasma concen-
tration of carboplatin (i.e. either increasing it during the overlap-
ping portion of that paradigm, or decreasing it during the sequential
paradigm). However, when the concentration of carboplatin was
analysed in both the overlapping and sequential paradigms, only a
modest (< 20%) increase in carboplatin concentration was observed
in the Cereport groups with no significant difference between
the two dosing conditions observed. Moreover, when Kis were
computed for the groups (thus factoring into the equation the
different plasma concentration gradients), a significant difference
in uptake effect of Cereport still existed between the two paradigms
(Figure 5B). Thus, the small difference in carboplatin plasma
concentrations cannot account for the difference in carboplatin
delivery observed.
A third possible explanation involves the timing of the carbo-
platin Cmax (peak plasma concentration), relative to the Cereport
infusion. In the overlapping dosing condition the Cmax occurred
during the early part of the Cereport infusion, whereas in the
sequential paradigm the timing of the Cmax had just passed as the
Cereport infusion began. If an appreciable delay exists in the
BBTB permeability effects of i.v. Cereport infusions, this might
account for some of the difference observed between the two
dosing paradigms.
While an explanation for these findings will require additional
research, a number of salient points can be made about the small
difference in carboplatin plasma levels observed: (a) they do not
appear to exert a major influence on the uptake measures; (b) no
evidence of increased toxicological liability has been observed in
extensive human (Warkne et al, 1995; Grous et al, 1996; Gregor et
al, 1997; Prados et al, 1997; Chow et al, 1998) and animal (Riley
et al, 1998) studies; and (c) the phenomenon seems to be indepen-
dent of renal clearance, given that the difference was observed
within 10 min of Cereport, the fact that steady-state levels of
carboplatin apparently existed, and that the plasma half-life of
carboplatin is relatively long (i.e. 72 h).
Together, the data from this series of experiments with i.v.
Cereport offer evidence that carboplatin delivery into gliomas can
be enhanced when carboplatin is given as an infusion. The data
also provide important insight into some of the essential dosing
parameters required to use this method successfully, demon-
strating the complex and transient nature of the vascular phenom-
enon exploited by this approach. They point to the importance of
increasing the empirical data base to help in the design of new
clinical dosing protocols, because entirely unexpected outcomes
can result. Presumably, as results from additional research gradu-
ally accumulate, including the use of a wider range of chemo-
therapeutic agents, the empirical foundation supporting this novel
approach to treating gliomas will be strengthened further, and the
nuances underlying the approach will become increasingly clear.
This should facilitate accurate predictions of the optimal dosing
paradigms for different situations or circumstances. The system-
atic series of experiments reported here offers an essential step in
that direction and emphasizes that the optimal condition for
increasing uptake of carboplatin with Cereport includes initiation
of the carboplatin infusion several minutes prior to Cereport, while
maintaining a period of overlap in the two infusions.
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